New Public Awareness Campaign Launched to Promote Awareness of Pelvic Floor Disorders and Treatment Options for Women
These Disorders Affect Nearly 30 Million American Women; New Research Shows High Prevalence of Patients Not Understanding Their Treatment Options

NATICK, Mass., Oct. 3, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is a founding member of the Pelvic Floor Disorders (PFD) Alliance, a first-of-its-kind partnership formed to raise awareness of Pelvic Floor Disorders (PFDs) and help improve the quality of life for women with PFD through education and access to a wide variety of non-surgical and surgical treatment options. The alliance includes leaders in medical device, pharmaceutical and urogynecological industries, physicians and societies.

The lack of awareness and stigma surrounding PFDs led to the development of the PFD Alliance and a new public awareness campaign called, "Break Free Today from PFDs."  The campaign intends to help women understand the facts about PFDs and empower them with information to talk with their doctors about treatment options that can lead to improved quality of life.  The campaign will reach patients through local outreach events and online at www.voicesforpfd.org/breakfree.  

"Pelvic Floor Disorders are very common, yet women often avoid the topic for a variety of reasons," said Karen Noblett, M.D., professor and division director for urogynecology at the University of California, Irvine. "Pelvic Floor Disorders can impact various aspects of life, everything from exercise and travel to confidence and sexual intimacy, but women should not be embarrassed or feel like they just have to live with it.  Instead, we want to empower women to speak up with confidence."

New research by the PFD Alliance shows that 90 percent of Americans underestimate or are unsure about the prevalence of PFDs, which currently impacts an estimated 28 million women in the United States alone.  This suggests women don't seek treatment for PFDs.  The research further indicates that nearly 40 percent of women in the United States would manage a PFD with over-the-counter supplies, such as pads, or wait until they are uncomfortable enough to seek treatment.  Although many minimally invasive procedures are available to correct PFDs, only one in five women reports she would undergo a surgical procedure to correct a PFD. 

Pelvic Floor Disorders occur when women have weakened pelvic muscles or tears in the connective tissues.  The following risk factors for PFDs include:

Genetic and Life-Stage Risk Factors

  • AGE:  The strength of the pelvic floor deteriorates as women age, possibly leading to the development of PFDs, which include pelvic organ prolapse and urinary incontinence.
  • RACE:  Caucasian women are more likely than African American and Asian women to develop prolapse.
  • PREGNANCY and CHILDBIRTH:  Childbirth can contribute to the development of PFDs. Vaginal births double the rate of pelvic floor disorders compared to Cesarean deliveries and women who never gave birth.
  • MENOPAUSE:  The pelvic floor muscles often weaken during menopause, which can lead to the development of pelvic organ prolapse.

Lifestyle Risk Factors

  • OBESITY:  Overweight or obese women often lack strength in their pelvic muscles and are at an increased risk of developing pelvic organ prolapse and urinary incontinence.
  • SMOKING: Women who smoke increase their risk of developing urinary incontinence and pelvic organ prolapse.

"Boston Scientific remains committed to advancing quality patient care for women with pelvic floor disorders," said Karen Prange, senior vice president and president, Urology and Women's Health division of Boston Scientific.  "Robust patient education tools are the foundation of a meaningful dialogue between a physician and a patient as an individualized treatment plan is developed. We look forward to a continued partnership among PFD Alliance members to ensure that both physicians and patients have access to comprehensive educational resources."

For additional information about the PFD Alliance and events in your community, visit www.voicesforpfd.org/breakfree.  

The founding members of the PFD Alliance include Boston Scientific, the American Urogynecologic Society, the Foundation for Female Health Awareness and Merck Consumer Care.  Other organizations are expected to join the PFD Alliance later this year and beyond.

About Boston Scientific Women's Health

Boston Scientific Women's Health continues to demonstrate their commitment to physicians and their patients through product innovation, clinical excellence and the development of robust professional programs. They pioneered the creation of the Pelvic Floor Institute which provides physicians an interactive platform to view an array of webcasts, procedural videos, animations and other patient education tools. Also, over 100 educational programs take place every year, to meets physician needs in advancing pelvic floor knowledge. Visit www.pelvic-floor-institute.com for more information.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties.  For more information, please visit: www.bostonscientific.com.  

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding our business plans and PFD Alliance partnerships.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. 

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.

 

CONTACT: 

Steven Campanini


508-652-5740 (office)


Media Relations


Boston Scientific Corporation


steven.campanini@bsci.com




Michael Campbell


508-650-8023 (office)


Investor Relations


Boston Scientific Corporation


investor_relations@bsci.com

SOURCE Boston Scientific Corporation

Top